MARKET

BIVI

BIVI

Biovie Inc
NASDAQ
1.190
-0.070
-5.56%
After Hours: 1.190 0 0.00% 16:10 11/12 EST
OPEN
1.240
PREV CLOSE
1.260
HIGH
1.240
LOW
1.160
VOLUME
163.10K
TURNOVER
--
52 WEEK HIGH
3.790
52 WEEK LOW
0.8200
MARKET CAP
12.76M
P/E (TTM)
-0.4168
1D
5D
1M
3M
1Y
5Y
1D
BioVie Stockholders Approve Directors, Auditor, and Equity Plan
TipRanks · 2d ago
BioVie Reports Distinct Biomarker Responses In Phase 2 Long COVID Trial; Stock Down
NASDAQ · 3d ago
BioVie presents new biomarker data from ADDRESS-LC trial of bezisterim
TipRanks · 3d ago
BioVie Presents New Biomarker Data From ADDRESS-LC Trial Of Bezisterim In Long COVID; Analyses Suggest Single Efficacy Endpoint May Not Adequately Capture Clinically Meaningful Response To Therapeutic Intervention Across Biological Diversity Of Long Covid
Benzinga · 3d ago
Weekly Report: what happened at BIVI last week (1102-1106)?
Weekly Report · 3d ago
Fusion Power, Global Capital, Branded Streaming and Neurology Breakthroughs: New to The Street Show #779 Premieres Tonight on Bloomberg Television
Barchart · 5d ago
BioVie Inc. Announces Pricing of $4.74 Million Registered Direct Offering and Concurrent Private Placement
NASDAQ · 5d ago
BioVie Closes $4.74 Million Registered Direct Offering
TipRanks · 6d ago
More
About BIVI
BioVie Inc. is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease. In neurodegenerative disease, the Company's drug candidate bezisterim inhibits inflammatory activation of extracellular signal-regulated kinase and the transcription factor nuclear factor-kB, and the associated neuroinflammation and insulin resistance, but not ERK and NFkB homeostatic functions (such as insulin signaling and neuron growth and survival). Both neuroinflammation and insulin resistance are drivers of Alzheimer’s disease (AD) and Parkinson’s disease (PD). Persistent systematic inflammation and neuroinflammation are key features in patients with neurological symptoms of long COVID. In liver disease, the Company's orphan drug candidate BIV201, is being evaluated for Phase III clinical testing for the reduction of further decompensation in participants with liver cirrhosis and ascites.

Webull offers BioVie Inc stock information, including NASDAQ: BIVI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BIVI stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BIVI stock methods without spending real money on the virtual paper trading platform.